

WHAT IS EASYHALER®

A carbon neutral, multidose inspiratory flow driven, metered dose dry powder inhaler developed for the treatment of asthma and chronic obstructive pulmonary disease.¹ Easyhaler generates accurate and consistent dose delivery – even with low inhalation flows.²



BUFOMIX
EASYHALER®
(Budesonide/formoterol fumarate dihydrate)

SALFLUMIX
EASYHALER®
(Fluticasone propionate/salmeterol xinafoate)



Carbon
Neutral
Product

ORION



(Budesonide/formoterol fumarate dihydrate)



ASTHMA INDICATIONS: For the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations in adults and adolescents (>12 years). Bufomix Easyhaler can be used as an anti-inflammatory reliever therapy (AIR), fixed dose maintenance therapy or anti-inflammatory reliever plus maintenance therapy (MART).³

| Strength | PBS Item Number | Clinical Criteria | PBS Streamlined Authority Code | Streamlined Authority 60 Days | Max Dispensed Qty | A-Flagged |
|--------------------------|-----------------|--------------------------------|--------------------------------|-------------------------------------|-------------------|-------------------------------------|
| 200/6 Bufomix Easyhaler | 14166N | Mild Asthma (AIR) | 10464 | NO | 2 | NO |
| | 14159F | Fixed dose maintenance | 10538 | NO | 2 | NO |
| | 14151T | Maintenance & reliever (MART) | 7970 | NO | 2 | NO |
| 400/12 Bufomix Easyhaler | 13258T | Fixed dose maintenance >18yrs | 7979 | NO | 2 | <input checked="" type="checkbox"/> |
| | 14398T | Fixed dose maintenance >18 yrs | 15617 | <input checked="" type="checkbox"/> | 4 | <input checked="" type="checkbox"/> |

COPD INDICATION: For the symptomatic treatment of moderate to severe COPD (FEV1 ≤50% predicted normal) in adults with frequent symptoms despite long-acting bronchodilator use, and/or a history of recurrent exacerbations. Bufomix Easyhaler is not indicated for the initiation of bronchodilator therapy in COPD.³

| Strength | PBS Item Number | Clinical Criteria | PBS Streamlined Authority Code | Streamlined Authority 60 Days | Max Dispensed Qty | A-Flagged |
|--------------------------|-----------------|---|--------------------------------|-------------------------------------|-------------------|-------------------------------------|
| 200/6 Bufomix Easyhaler | | This strength is not PBS subsidised for the treatment of COPD | | | | |
| 400/12 Bufomix Easyhaler | 13258T | Maintenance or symptom relief | 10121 | NO | 2 | <input checked="" type="checkbox"/> |
| | 14398T | Maintenance or symptom relief | 15548 | <input checked="" type="checkbox"/> | 4 | <input checked="" type="checkbox"/> |

Each inhaler contains 60 actuations and includes a dose counter and protective cover. Discard 1 month after removing the inhaler from the foil bag.

For patients to receive EASYHALER, prescribe BUFOMIX EASYHALER and the box.



(Fluticasone propionate/salmeterol xinafoate)



ASTHMA INDICATIONS: For the regular treatment of asthma, where the use of a combination product is appropriate. This may include patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids or patients who are symptomatic on current inhaled corticosteroid therapy.⁴

| Strength | PBS Item Number | Clinical Criteria | PBS Streamlined Authority Code | Streamlined Authority 60 Days | Max Dispensed Qty | A-Flagged |
|----------------------------|-----------------|-------------------------------|--------------------------------|-------------------------------------|-------------------|-------------------------------------|
| 250/50 Salflumix Easyhaler | 8431R | Maintenance or symptom relief | 15138 | NO | 1 | <input checked="" type="checkbox"/> |
| | 14449L | Maintenance or symptom relief | 15693 | <input checked="" type="checkbox"/> | 2 | <input checked="" type="checkbox"/> |
| 500/50 Salflumix Easyhaler | 8432T | Maintenance or symptom relief | 15118 | NO | 1 | <input checked="" type="checkbox"/> |
| | 14450M | Maintenance or symptom relief | 15714 | <input checked="" type="checkbox"/> | 2 | <input checked="" type="checkbox"/> |

COPD INDICATION: For the symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. SALFLUMIX EASYHALER is not indicated for the initiation of bronchodilator therapy in COPD.⁴

| Strength | PBS Item Number | Clinical Criteria | PBS Streamlined Authority Code | Streamlined Authority 60 Days | Max Dispensed Qty | A-Flagged |
|----------------------------|---|-------------------------------|--------------------------------|-------------------------------------|-------------------|-------------------------------------|
| 250/50 Salflumix Easyhaler | This strength is not PBS subsidised for the treatment of COPD | | | | | |
| 500/50 Salflumix Easyhaler | 8432T | Maintenance or symptom relief | 10121 | NO | 1 | <input checked="" type="checkbox"/> |
| | 14450M | Maintenance or symptom relief | 15548 | <input checked="" type="checkbox"/> | 2 | <input checked="" type="checkbox"/> |

Each inhaler contains 60 actuations and includes a dose counter and protective cover. The SALFLUMIX EASYHALER 250/50 inhaler should be discarded 1 month after first opening the foil bag. The SALFLUMIX EASYHALER 500/50 inhaler should be discarded 2 months after first opening the foil bag.

For patients to receive EASYHALER, prescribe SALFLUMIX EASYHALER and the box.



(Budesonide/formoterol fumarate dihydrate)



(Fluticasone propionate/salmeterol xinafoate)

**SCAN THE QR CODE TO ACCESS CLINICAL INFORMATION,
INSTRUCTIONS FOR USE OR TO ORDER A DEMO DEVICE.**



References: **1.** Carbon Neutral Product Certificate for Easyhaler product range. Available on request from Orion Pharma. **2.** Haikarainen J, et al. Chron Respir Dis 2018;15(3):265-71. **3.** Bufomix Easyhaler Product Information, July 17, 2023. **4.** Salflumix Easyhaler Product Information, August 18, 2023.

PBS information: Authority required (STREAMLINED). Refer to PBS Schedule for full authority information.

Before prescribing, please review the full Product Information available via the QR codes or from
<https://www.orionpharma.com.au/products/primary-care-products>



BUFOMIX
PRODUCT
INFORMATION



SALFLUMIX
PRODUCT
INFORMATION

EASYHALER® is a registered trademark of Orion Corporation Finland.
Orion Pharma, Level 24, Tower 3, 300 Barangaroo Ave Sydney NSW 2000 Australia
www.orionpharma.com.au | contactausaustralia@orionpharma.com For medical information or to
report an adverse event PH: 1800 861 913 or EMAIL: medical.ANZ@pharmalex.com
Date of preparation: January 2025. EH_AU_2025_03

